GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Other Cash Payments from Operating Activities

Blueprint Medicines (STU:2L9) Other Cash Payments from Operating Activities


View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Other Cash Payments from Operating Activities?

Other Cash Payments from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Blueprint Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Other Cash Payments from Operating Activities
Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.